Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SELL Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
https://www.prnewswire.com/news-releases/seelos-therapeutics-inc-announces-4-0-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market-under-nasdaq-rules-302045669.html
I voted No to Proxy. More dilution planned and increase in outstanding shares.
You are a master of two word messages all over Ihub.
Form 424B5 - Prospectus [Rule 424(b)(5)]
https://ih.advfn.com/stock-market/NASDAQ/seelos-therapeutics-SEEL/stock-news/92670943/form-424b5-prospectus-rule-424b5
CONSTANT “DUMPING” by 👇👇👇
https://investorshub.advfn.com/boards/profile.aspx?user=114150
ANNOYING DUMPING
What an annoying asshole
RS 1:30 tomorrow. I’m holding. Never know if good news is released.
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)
PUBLISHED
NOV 27, 2023 8:00AM EST
https://www.nasdaq.com/press-release/seelos-therapeutics-announces-the-selection-of-sls-002-intranasal-racemic-ketamine
SEEL will retain it’s Nasdaq standing.
11.03.2023 8-K Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 1, 2023, Seelos Therapeutics, Inc. (the “Company”) received written notice (the “First Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until April 29, 2024, to regain compliance. The First Notice states that the Nasdaq staff will provide written confirmation that the Company has achieved compliance with Rule 5550(a)(2) if at any time before April 29, 2024, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days.
About ready to avg. down but waiting for a dip to .17 area.
.199 now.
SEEL.....from .1651 to .2020 in 4 days is good enough for me
SEEL, and TVTX are my bounce plays for next week. My SEEL pps average is around .1651
Looks to be artificially took down with 3 days of more buying then selling
Phase 2 failed and next day dilution. One two punch.
one more thing : my other message is for 29 december.
Followers
|
243
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
30353
|
Created
|
09/14/05
|
Type
|
Free
|
Moderators |
Seelos Therapeutics is exploring new ways to think about and treat central nervous system (CNS) disorders in neurological diseases and disorders and in rare diseases. Our trials are designed to further evaluate the safety and efficacy of our acquired assets. These come to Seelos with well characterized efficacy and safety, thereby avoiding much of the lengthy and burdensome process of preclinical R&D.
By working with clinically ready novel and reformulated compounds we will move from asset acquisition to meaningful data readouts in an expedited and efficient fashion. It is our goal to develop unique and disruptive therapies and approaches to improve treatment of large known diseases, offer new treatments for large unmet or recently characterized indications as well as advance therapies for orphan indications.
Our approach to this process will require development that is appropriate and efficient for a company our size in the scope of work each program requires in regards to trial size and duration.
We invite you to stay update on the progress of our assets in our clinical development programs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |